Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sanofi Invests €170M in New Vaccine Facility in France | Contract Pharma

What are you searching for?

Sign in
Breaking News

Sanofi Invests €170M in New Vaccine Facility in France

Will allow Sanofi Pasteur to expand the global supply of its new quadrivalent influenza vaccine VaxigripTetra

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sanofi is investing €170 million to expand a vaccine manufacturing site in Val de Reuil, France. The new facility will allow Sanofi Pasteur, the Vaccines unit of Sanofi, to expand the global supply of its new quadrivalent influenza vaccine, VaxigripTetra. The new vaccine contains two A strains and two B strains of influenza virus, as per World Health Organization recommendation. Sanofi plans to complete the expansion by 2021, and begin producing vaccines at this site in 2022.

“This project brings together the expertise of our people with our leading industrial know-how and illustrates our commitment to manufacturing excellence solutions,” said Philippe Luscan, Executive Vice President, Global Industrial Affairs, Sanofi. “Our investment underlines Sanofi’s intent to strengthen our industrial capacities in France as a major centre of influenza vaccines production for worldwide markets.”

This investment is one of several major investments Sanofi has made recently to improve and expand its vaccine production capacities across France, the U.S. and Mexico.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics